Synthetic human Aβ1−42 peptides (>95% pure by high performance liquid chromatography and mass spectrometry tests) were dissolved in dimethylsulfoxide (DMSO) to a concentration of 5 mM.
It is conceivable that the mass spectrometry test may detect acute rejections that are missed by biopsy because of the focal nature of the rejection in the allograft or because of potential biopsy sampling errors.
Clinical data include demographics of recipient and donor, immunologic parameters like HLA match and pre-formed antibodies, calculated GFR at the time of biopsy, any relevant diagnoses of the allograft like hydronephrosis or delayed graft function, any relevant factors at the time of biopsy which are potential confounders of the mass spectrometry test.
Meconium samples were analyzed by a reference laboratory (ARUP Laboratories) using enzyme-linked immunosorbent assay (ELISA) with confirmation by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS) testing [ 16, 17].
If the lab notices any abnormality, it conducts an isotope ratio mass spectrometry (IRMS) test to determine whether the testosterone is exogenous, or came from outside the body.
All samples analyzed by mass spectrometry were tested as being negative for serum/plasma contamination by MALDI-FT-ICR measurements.
We also used mass spectrometry to test AtBRI1-GC for adenylyl cyclase activity in the presence of 1 mM ATP as the substrate and could not detect significant amounts of cAMP generated after 20 min. of incubation (result not shown) thus indicating that, at least in vitro, the recombinant protein has the predicted substrate preference for GTP.
For mass spectrometry (MS), test solutions were prepared by diluting the stock solutions with ACN/H2O mixture.
Therefore, the aim of this multicentre prospective phase 3 diagnostic accuracy study is to investigate if the mass spectrometry (MS) test developed by Metzger et al. [ 13], is useful in a representative setting of the clinical routine post-transplant care.
FDA and the National Institutes of Health jointly published mock presubmission reviews of two examples of multiplex proteomic tests, one a mass spectrometry-based test and one protein array-based test.
